Tarlatamab for SCLC Brain Metastases

Sponsor
Maastricht University Medical Center
Study ID
NCT07402343
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tarlatamab — DRUG
    Cycle 1: 1 mg on day 1, followed by 10 mg on days 8 and 15 Cycles thereafter: 10 mg every two weeks, in cycles of 28 days Treatment continues till unacceptable toxicity or disease progression

Study Details

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).

Key Dates

First listed
Feb 11, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Feb 28, 2029
Completion
Feb 28, 2030

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tarlatamab
    Tarlatamab intravenous: 1 mg on day 1, followed by 10 mg on days 8 and 15 of cycle 1; thereafter every 2 weeks in cycles of 28 days

Primary Outcome Measure

Intracranial overall response rate (ORR) [ Time Frame: Up to 36 months ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies